Abstract:Cell division cycle 25B (CDC25B), a member of the CDC25 phosphatase family, plays a key role in cell cycle regulation. Studies have suggested its carcinogenic potential in various cancers, but the role of CDC25B in the development of hepatocellular carcinoma (HCC) remains poorly understood. The aim of this study was to clarify the role of CDC25B in HCC using bioinformatics and experiments. CDC25B expression data of HCC cancer tissues and paracancerous normal samples were obtained from The Cancer Gene Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and the relationship between CDC25B expression and the prognosis and degree of tumor differentiation of HCC patients was analyzed. CDC25B expression was verified in clinical HCC tissue samples using fluorescence quantitative polymerase chain reaction (q‐PCR) and protein immunoblotting (Western blot). Gene set enrichment analysis (GSEA) was used to identify signaling pathways enriched in CDC25B expression, and differential genes (DEGs) were used to screen out coexpressed hub genes and construct protein‐protein interaction (PPI) networks. 5‐Ethynyl‐2 ′ ‐deoxyuridine (EDU) staining was used to compare the proliferation and differentiation ability of the HCC cell line (HCC‐LM3) after knockdown of CDC25B. Finally, we investigated the mutation of CDC25B in HCC and the relationship between CDC25B expression and tumor cell infiltration of lymphocytes and some immune checkpoints as well as drug sensitivity. CDC25B was overexpressed in HCC tissues and correlated with poor prognosis and the degree of tumor differentiation in patients with HCC. The GSEA and PPI networks together revealed significantly upregulated signaling pathways, as well as functions, associated with the development of HCC when CDC25B was overexpressed. The EDU assay demonstrated that the ability of cells to differentiate value addedly was markedly reduced following the downregulation of CDC25B expression in HCC‐LM3s. CDC25B was also involved in the formation of the tumor microenvironment (TME) and immune processes in HCC, and the high expression of CDC25B made patients less sensitive to some drugs. CDC25B can be used as a biomarker and immunotherapeutic target for poor prognosis and partial drug sensitivity in HCC, providing new ideas for HCC treatment.

IGF2BP2 Promotes Glycolysis and Hepatocellular Carcinoma Stemness by Stabilizing CDC45 Mrna Via M6a Modification.

LCAT1 is an Oncogenic LncRNA by Stabilizing the IGF2BP2-CDC6 Axis

IGF2BP3 Enhances the Growth of Hepatocellular Carcinoma Tumors by Regulating the Properties of Macrophages and CD8+ T Cells in the Tumor Microenvironment

Epigenetically associated IGF2BP3 upregulation promotes cell proliferation by regulating E2F1 expression in hepatocellular carcinoma

IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism

Loss of MiR-192-5p Initiates a Hyperglycolysis and Stemness Positive Feedback in Hepatocellular Carcinoma.

IGF2BP2 Regulates DANCR by Serving As an N6-methyladenosine Reader.

ASF1B Serves As a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma

Metabolic Enzyme SLC27A5 Regulates PIP4K2A pre‐mRNA Splicing as a Noncanonical Mechanism to Suppress Hepatocellular Carcinoma Metastasis

Expression of Cell Division Cycle Protein 45 in Tissue Microarrays and the CDC45 Gene by Bioinformatics Analysis in Human Hepatocellular Carcinoma and Patient Outcomes.

CDC25B Is a Prognostic Biomarker Associated With Immune Infiltration and Drug Sensitivity in Hepatocellular Carcinoma

PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition

The IGF2BP2-lncRNA TRPC7-AS1 axis promotes hepatocellular carcinoma cell proliferation and invasion

Targeting Mybbp1a Suppresses HCC Progression Via Inhibiting IGF1/AKT Pathway by CpG Islands Hypo-Methylation Dependent Promotion of IGFBP5.

Hsa_circ_0026134 Expression Promoted TRIM25- and IGF2BP3-mediated Hepatocellular Carcinoma Cell Proliferation and Invasion Via Sponging Mir-127-5p

IGF2 loss of imprinting enhances colorectal cancer stem cells pluripotency by promoting tumor autophagy

IGF2BP3 enhances lipid metabolism in cervical cancer by upregulating the expression of SCD

Elevated expression of HIGD1A drives hepatocellular carcinoma progression by regulating polyamine metabolism through c-Myc–ODC1 nexus

IGF2BP3 Promotes the Progression of Colorectal Cancer and Mediates Cetuximab Resistance by Stabilizing EGFR Mrna in an M6a-Dependent Manner

The m6A reader IGF2BP2 promotes ESCC progression by stabilizing HDGF mRNA

Prognostic implications of cell division cycle protein 45 expression in hepatocellular carcinoma